期刊
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
卷 50, 期 2, 页码 237-241出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijantimicag.2017.03.011
关键词
Fosfomycin; Combination therapy; KPC-producing Klebsiella pneumoniae; Synergistic effect; Bactericidal effect
资金
- Key Research and Development Program from Zhejiang Province [2015C03032]
The increasing prevalence of KPC-producing Klebsiella pneumoniae (KPC-Kp)strains poses a serious threat to patients. Therapeutic options are limited to colistin, fosfomycin, tigecycline and selected aminoglycosides. Although the combination of fosfomycin with other antimicrobials is recommended, data regarding possible synergistic activity in vitro and in vivo appear inconsistent. Here we report that five drug combinations (fosfomycin combined with imipenem, ertapenem, tigecycline, colistin or amikacin) had a significant additive effect against 136 KPC-Kp strains in an in vitro chequerboard assay. In addition, time-kill assays revealed that fosfomycin enhanced the bactericidal activity of the five other antimicrobial agents. Moreover, owing to its persistent bactericidal effect, the combination of fosfomycin plus amikacin is an effective therapeutic candidate for infections by KPC-producing organisms. (C) 2017 The Authors. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据